<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04437602</url>
  </required_header>
  <id_info>
    <org_study_id>2019-02661</org_study_id>
    <nct_id>NCT04437602</nct_id>
  </id_info>
  <brief_title>Added Value of Preoperative Contrast Enhanced Mammography in Staging of Malignant Breast Lesions</brief_title>
  <acronym>PROCEM</acronym>
  <official_title>Added Value of Preoperative Contrast Enhanced Mammography (PROCEM) in Staging of Malignant Breast Lesions - a Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Halland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Halland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients diagnosed with breast cancer after routine assessment with digital mammography and
      ultrasound and scheduled for primary surgery are included in the trial. The patients are
      randomized 1:1 to go through additional contrast enhanced mammography (CEM) or no further
      imaging preoperatively. Primary endpoint is rate of patients with change of treatment: a)
      mastectomy instead of partial mastectomy due larger unifocal or multifocal extent, b) partial
      mastectomy instead of mastectomy due to improved demarcation of the tumour area, c) bilateral
      surgery instead of unilateral due to findings of contralateral cancer, d) neoadjuvant therapy
      instead of primary surgery due to more advanced disease. Rate of reoperation and rate of
      avoidable mastectomies are secondary endpoints.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective Randomized Trial</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with change of primary treatment due to findings at additional CEM</measure>
    <time_frame>Within two months after diagnosis of breast cancer</time_frame>
    <description>Mastectomy instead of partial mastectomy due to findings of multifocal disease, mastectomy instead of partial mastectomy due to larger unifocal extent, partial mastectomy instead of mastectomy due to improved demarcation of tumour area, bilateral surgery due to findings of contralateral cancer, primary neoadjuvant treatment instead of primary surgery due to more advanced disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of reoperations</measure>
    <time_frame>Within three months after diagnosis of breast cancer</time_frame>
    <description>Number of reoperations due to inadequate margins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of avoidable mastectomies</measure>
    <time_frame>Within three months after diagnosis of breast cancer</time_frame>
    <description>Patients operated with mastectomy where histopathology shows extent less than 3 cm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>CEM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in experimental arm will go through additional preoperative staging with contrast enhanced mammography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No CEM</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in No intervention arm will go through no additional preoperative imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Contrast Enhanced Mammography (CEM)</intervention_name>
    <description>Additional CEM in preoperative staging</description>
    <arm_group_label>CEM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned primary surgery for suspicious or verified breast malignancy Age of 18 years
             and above Signed informed consent

        Exclusion Criteria:

          -  Planned neoadjuvant therapy On-going pregnancy Iodinated contrast agent allergy Renal
             failure (abnormal S-creatinine) Untreated thyreotoxicosis Inability to understand and
             comprehend oral and written information of the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Breast cancer is very uncommon among men.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina Ahsberg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Halland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristina Ahsberg, PhD</last_name>
    <phone>+46 705 504120</phone>
    <email>kristina.ahsberg@med.lu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Halland Hospital Halmstad</name>
      <address>
        <city>Halmstad</city>
        <zip>301 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Kristina Ahsberg, PhD</last_name>
      <phone>+46 705 504120</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <zip>252 23</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Pia Lindblom, PhD</last_name>
      <email>pia.lindblom@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Hospital Kristianstad</name>
      <address>
        <city>Kristianstad</city>
        <zip>291 33</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Tor Svensj√∂, PhD</last_name>
      <email>tor.svensjo@skane.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contrast Enhanced Mammography</keyword>
  <keyword>Preoperative staging</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

